SequelSEC

Cardiff Oncology, Inc. CRDF

Biological Products, (No Diagnostic Substances) · CIK 0001213037 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$508.00K
Fiscal year ended 2026-06-30
Operating income
-$42.27M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$205.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue346.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity4.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue960.0%88th
FCF margin-6402.5%16th
Net margin-7732.0%17th
Operating margin-8256.3%18th
CapEx / revenue7.4%64th
Revenue YoY growth-13.2%36th
Current ratio3.67x42th

Cardiff Oncology, Inc. (CRDF) reported revenue of $508.00K and net income of -$40.05M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Cardiff Oncology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Cardiff Oncology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$508.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$42.27M
Net income-$40.05M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$16.82M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Cardiff Oncology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$9.20M
Total assets$37.33M
Current assets$35.59M
Total liabilities$10.80M
Current liabilities$10.80M
Total equity incl. NCI$26.53M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$189.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.99M

Cash flow

Cardiff Oncology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$40.85M
Capital expendituresUnavailable
Investing cash flow$36.44M
Financing cash flow$2.83M
Net change in cash-$1.59M
Stock-based compensation$5.22M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$351.00K

Derived

Cardiff Oncology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-8320.1%
FCF marginUnavailable
SBC / revenue1028.5%
Current ratio3.30x
Revenue YoY growth-7.0%
Net margin-7884.1%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRDF in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.